Latest News for UCBJY
Belgian drugmaker UCB has entered into an agreement to licence Antengene's experimental autoimmune disease therapy ATG-201 and associated technology, paying $60 million up front and over $1.1 billion more if certain milestones are met, the Chinese drugmaker said Wednesday.
UCB SA (UCBJY) Q4 2025 Earnings Call Transcript
UCB SA (UCBJY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
UCB (OTCMKTS:UCBJY - Get Free Report) and Minerva Neurosciences (NASDAQ: NERV - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations. Valuation and Earnings This table compares UCB and Minerva
UCB SA (OTCMKTS:UCBJY - Get Free Report)'s stock price crossed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $137.71 and traded as high as $141.49. UCB shares last traded at $141.1670, with a volume of 32,273 shares traded. Wall Street Analysts Forecast Growth
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for UCBJY.
Senate Trading
No Senate trades found for UCBJY.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.